- In January 2025, Merck announced the launch of its next-generation fertility treatment, a novel hormone therapy designed to improve ovarian stimulation outcomes for women undergoing in-vitro fertilization (IVF). The new therapy leverages advanced recombinant technology to enhance egg maturation while reducing side effects associated with traditional hormone treatments
- In October 2024, at the ASRM 2024 conference, CooperSurgical unveiled its latest AI-powered embryo selection tool, designed to improve implantation success rates by analysing embryo quality with higher precision. The company also presented data supporting the use of time-lapse imaging and AI algorithms to optimize IVF outcomes
- In September 2024, Ferring Pharmaceuticals received FDA approval for a ground breaking oral gonadotropin therapy, offering a more patient-friendly alternative to traditional injectable fertility drugs. The therapy aims to simplify treatment protocols while maintaining high efficacy in ovarian stimulation
- In September 2024, Igenomix launched an innovative non-invasive embryo testing technology, which allows for the genetic screening of embryos without the need for biopsy. This advancement provides a safer and more accurate way to assess embryo viability, improving success rates for couples undergoing fertility treatments
